Sartorius Stedim Biotech Statistics

Total Valuation

Sartorius Stedim Biotech has a market cap or net worth of EUR 18.02 billion. The enterprise value is 20.41 billion.

Market Cap	18.02B
Enterprise Value	20.41B

Important Dates

The next estimated earnings date is Tuesday, January 28, 2025.

Earnings Date	Jan 28, 2025
Ex-Dividend Date	n/a

Share Statistics

Sartorius Stedim Biotech has 97.31 million shares outstanding. The number of shares has increased by 3.60% in one year.

Current Share Class	n/a
Shares Outstanding	97.31M
Shares Change (YoY)	+3.60%
Shares Change (QoQ)	+3.02%
Owned by Insiders (%)	0.00%
Owned by Institutions (%)	12.00%
Float	29.47M

Valuation Ratios

The trailing PE ratio is 110.10 and the forward PE ratio is 45.62. Sartorius Stedim Biotech's PEG ratio is 2.25.

PE Ratio	110.10
Forward PE	45.62
PS Ratio	6.46
PB Ratio	4.66
P/TBV Ratio	n/a
P/FCF Ratio	35.78
P/OCF Ratio	n/a
PEG Ratio	2.25

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 30.43, with an EV/FCF ratio of 40.52.

EV / Earnings	127.07
EV / Sales	7.46
EV / EBITDA	30.43
EV / EBIT	51.16
EV / FCF	40.52

Financial Position

The company has a current ratio of 2.14, with a Debt / Equity ratio of 0.72.

Current Ratio	2.14
Quick Ratio	1.05
Debt / Equity	0.72
Debt / EBITDA	4.22
Debt / FCF	5.62
Interest Coverage	1.85

Financial Efficiency

Return on equity (ROE) is 5.02% and return on invested capital (ROIC) is 3.78%.

Return on Equity (ROE)	5.02%
Return on Assets (ROA)	3.12%
Return on Capital (ROIC)	3.78%
Revenue Per Employee	271,325
Profits Per Employee	15,929
Employee Count	10,662
Asset Turnover	0.34
Inventory Turnover	1.78

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -22.20% in the last 52 weeks. The beta is 0.67, so Sartorius Stedim Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.67
52-Week Price Change	-22.20%
50-Day Moving Average	185.05
200-Day Moving Average	191.25
Relative Strength Index (RSI)	50.74
Average Volume (20 Days)	57,596

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Sartorius Stedim Biotech had revenue of EUR 2.74 billion and earned 160.60 million in profits. Earnings per share was 1.68.

Revenue	2.74B
Gross Profit	1.19B
Operating Income	398.90M
Pretax Income	224.60M
Net Income	160.60M
EBITDA	645.70M
EBIT	398.90M
Earnings Per Share (EPS)	1.68

Full Income Statement

Balance Sheet

The company has 482.60 million in cash and 2.83 billion in debt, giving a net cash position of -2.35 billion or -24.14 per share.

Cash & Cash Equivalents	482.60M
Total Debt	2.83B
Net Cash	-2.35B
Net Cash Per Share	-24.14
Equity (Book Value)	3.94B
Book Value Per Share	39.78
Working Capital	862.60M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 866.30 million and capital expenditures -362.60 million, giving a free cash flow of 503.70 million.

Operating Cash Flow	866.30M
Capital Expenditures	-362.60M
Free Cash Flow	503.70M
FCF Per Share	5.18

Full Cash Flow Statement

Margins

Gross margin is 43.33%, with operating and profit margins of 14.58% and 5.87%.

Gross Margin	43.33%
Operating Margin	14.58%
Pretax Margin	8.21%
Profit Margin	5.87%
EBITDA Margin	23.60%
EBIT Margin	14.58%
FCF Margin	18.41%

Dividends & Yields

This stock pays an annual dividend of 0.69, which amounts to a dividend yield of 0.37%.

Dividend Per Share	0.69
Dividend Yield	0.37%
Dividend Growth (YoY)	-52.08%
Years of Dividend Growth	3
Payout Ratio	41.78%
Buyback Yield	-3.60%
Shareholder Yield	-3.23%
Earnings Yield	0.91%
FCF Yield	2.79%

Dividend Details

Stock Splits

The last stock split was on May 6, 2016. It was a forward split with a ratio of 6.

Last Split Date	May 6, 2016
Split Type	Forward
Split Ratio	6

Scores

Sartorius Stedim Biotech has an Altman Z-Score of 3.98.

Altman Z-Score	3.98
Piotroski F-Score	n/a